Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 3/2012

Open Access 01-03-2012 | Meta-analysis

Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis

Authors: P. Vejakama, A. Thakkinstian, D. Lertrattananon, A. Ingsathit, C. Ngarmukos, J. Attia

Published in: Diabetologia | Issue 3/2012

Login to get access

Abstract

Aims/hypothesis

This meta-analysis aimed to compare the renal outcomes between ACE inhibitor (ACEI)/angiotensin II receptor blocker (ARB) and other antihypertensive drugs or placebo in type 2 diabetes.

Methods

Publications were identified from Medline and Embase up to July 2011. Only randomised controlled trials comparing ACEI/ARB monotherapy with other active drugs or placebo were eligible. The outcome of end-stage renal disease, doubling of serum creatinine, microvascular complications, microalbuminuria, macroalbuminuria and albuminuria regression were extracted. Risk ratios were pooled using a random-effects model if heterogeneity was present; a fixed-effects model was used in the absence of heterogeneity.

Results

Of 673 studies identified, 28 were eligible (n = 13–4,912). In direct meta-analysis, ACEI/ARB had significantly lower risk of serum creatinine doubling (pooled RR = 0.66 [95% CI 0.52, 0.83]), macroalbuminuria (pooled RR = 0.70 [95% CI 0.50, 1.00]) and albuminuria regression (pooled RR 1.16 [95% CI 1.00, 1.39]) than other antihypertensive drugs, mainly calcium channel blockers (CCBs). Although the risks of end-stage renal disease and microalbuminuria were lower in the ACEI/ARB group (pooled RR 0.82 [95% CI 0.64, 1.05] and 0.84 [95% CI 0.61, 1.15], respectively), the differences were not statistically significant. The ACEI/ARB benefit over placebo was significant for all outcomes except microalbuminuria. A network meta-analysis detected significant treatment effects across all outcomes for both active drugs and placebo comparisons.

Conclusions/interpretation

Our review suggests a consistent reno-protective effect of ACEI/ARB over other antihypertensive drugs, mainly CCBs, and placebo in type 2 diabetes. The lack of any differences in BP decrease between ACEI/ARB and active comparators suggest this benefit is not due simply to the antihypertensive effect.
Appendix
Available only for authorised users
Literature
1.
Scheffel RS, Bortolanza D, Weber CS et al (2004) Prevalence of micro and macroangiopatic chronic complications and their risk factors in the care of outpatients with type 2 diabetes mellitus. Rev Assoc Med Bras 50:263–267PubMedCrossRef
2.
Ubink-Veltmaat LJ, Bilo HJ, Meyboom-de Jong B (2004) Microalbuminuria in patients with type 2 diabetes mellitus in general practice. Ned Tijdschr Geneeskd 148:2026–2030PubMed
3.
Wu AY, Kong NC, de Leon FA et al (2005) An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 48:17–26PubMedCrossRef
4.
Gall MA (1997) Albuminuria in non-insulin-dependent diabetes mellitus. Prevalence, causes, and consequences. Dan Med Bull 44:465–485PubMed
5.
Garg JP, Bakris GL (2002) Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 7:35–43PubMedCrossRef
6.
Klausen K, Borch-Johnsen K, Feldt-Rasmussen B et al (2004) Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110:32–35PubMedCrossRef
7.
Ravid M, Lang R, Rachmani R, Lishner M (1996) Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 156:286–289PubMedCrossRef
8.
Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G (2000) Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 35:1155–1165PubMedCrossRef
9.
Casas JP, Chua W, Loukogeorgakis S et al (2005) Effect of inhibitors of the renin–angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366:2026–2033PubMedCrossRef
10.
Kunz R, Friedrich C, Wolbers M, Mann JF (2008) Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148:30–48PubMed
11.
Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC (2004) Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 329:828PubMedCrossRef
12.
Sterne JA, Sutton AJ, Ioannidis JP et al (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343:d4002PubMedCrossRef
13.
Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2008) Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 61:991–996PubMedCrossRef
14.
Palmer TM, Peter JL, Sutton AJ, Moreno SG (2008) Contour-enhanced funnel plots in meta-analysis. Stata J 8:242–254
15.
Lu G, Ades AE (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23:3105–3124PubMedCrossRef
16.
Song F, Altman DG, Glenny AM, Deeks JJ (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326:472PubMedCrossRef
17.
Song F, Harvey I, Lilford R (2008) Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 61:455–463PubMedCrossRef
18.
Kashiwagi A (2007) Reduction of microalbuminuria in patients with type 2 diabetes. The Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 30:1581–1583PubMedCrossRef
19.
Estacio RO, Jeffers BW, Gifford N, Schrier RW (2000) Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23(Suppl 2):B54–B64PubMed
20.
Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S (1996) Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50:1641–1650PubMedCrossRef
21.
Chan JC, Ko GT, Leung DH et al (2000) Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 57:590–600PubMedCrossRef
22.
Lacourciere Y, Nadeau A, Poirier L, Tancrede G (1993) Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension 21:786–794PubMed
23.
Shiba T, Inoue M, Tada H et al (2000) Delapril versus manidipine in hypertensive therapy to halt the type-2-diabetes-mellitus-associated nephropathy. Diabetes Res Clin Pract 47:97–104PubMedCrossRef
24.
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253–259CrossRef
25.
Baba S (2001) Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 54:191–201PubMedCrossRef
26.
UK Prospective Diabetes Study Group (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317:713–720CrossRef
27.
Fogari R, Mugellini A, Zoppi A et al (2005) Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur J Clin Pharmacol 61:483–490PubMedCrossRef
28.
Fogari R, Preti P, Zoppi A et al (2002) Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens 15:1042–1049PubMedCrossRef
29.
Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Menard J (2004) Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 328:495PubMedCrossRef
30.
Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH (1997) Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 46:1182–1188PubMedCrossRef
31.
Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R (1998) Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 128:982–988PubMed
32.
Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M (1993) Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577–581PubMed
33.
Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860PubMedCrossRef
34.
Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869PubMedCrossRef
35.
Bilous R, Chaturvedi N, Sjolie AK et al (2009) Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 151(11–20):W13–W14
36.
Jerums G, Allen TJ, Campbell DJ et al (2004) Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with type 2 diabetes and microalbuminuria. Diabet Med 21:1192–1199PubMedCrossRef
37.
Sjolie AK, Klein R, Porta M et al (2008) Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 372:1385–1393PubMedCrossRef
38.
Marre M, Puig JG, Kokot F et al (2004) Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 22:1613–1622PubMedCrossRef
39.
Haller H, Ito S, Izzo JL Jr et al (2011) Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364:907–917PubMedCrossRef
40.
Fogari R, Zoppi A, Corradi L et al (1999) Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 13:47–53PubMedCrossRef
41.
Ahmad J, Siddiqui MA, Ahmad H (1997) Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 20:1576–1581PubMedCrossRef
42.
Lebovitz HE, Wiegmann TB, Cnaan A, et al. (1994) Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int (Suppl 45):S150–S155
43.
Ruggenenti P, Fassi A, Ilieva AP et al (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941–1951PubMedCrossRef
44.
Mosconi L, Ruggenenti P, Perna A, Mecca G, Remuzzi G (1996) Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Kidney Int Suppl 55:S91–S93PubMed
45.
Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S (2007) Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertens Res 30:325–334PubMedCrossRef
Metadata
Title
Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis
Authors
P. Vejakama
A. Thakkinstian
D. Lertrattananon
A. Ingsathit
C. Ngarmukos
J. Attia
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 3/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2398-8

Other articles of this Issue 3/2012

Diabetologia 3/2012 Go to the issue

Article

Elevated levels of renal and circulating Nop-7-associated 2 (NSA2) in rat and mouse models of diabetes, in mesangial cells in vitro and in patients with diabetic nephropathy

Article

The course of depressive symptoms in primary care patients with type 2 diabetes: results from the Diabetes, Depression, Type D Personality Zuidoost-Brabant (DiaDDZoB) Study

Article

Increased metabolic rate and insulin sensitivity in male mice lacking the carcino-embryonic antigen-related cell adhesion molecule 2

Article

Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data

Article

Age at menarche is associated with prediabetes and diabetes in women (aged 32–81 years) from the general population: the KORA F4 Study

Article

Small fibre dysfunction, microvascular complications and glycaemic control in type 1 diabetes: a case–control study

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits